Dyskinesia Efficacy (PP population) – CDRS Scales

Variable	Difference (PP Population)		
	2.5 mg - Test Session 1 Placebo	5 mg - Test Session 1 Placebo	7.5 mg - Test Session 1 Placebo
Primary Analysis			
CDRS - Mean AUC (0-3h)	-0.766 (1.679)	-1.27 (1.36)	-0.641 (1.405)
	p=0.0898	p=0.0007	p=0.0467
Secondary Analysis			
Highest observed CDRS after study medication	-0.417 (2.053)	-0.611 (1.451)	-0.194 (1.582)
	p=0.4946	p=0.1040	p=0.5126
Rush Dyskinesia Scale Mean AUC (0-3h)	-0.049 (0.302)	-0.201 (0.277)	-0.079 (0.248)
	p=0.5355	p=0.0085	p=0.1632
Mean Rush DRS rating after study medication	-0.074 (0.329)	-0.222 (0.308)	-0.109 (0.270)
	p=0.4323	p=0.0094	p=0.1287

Mean (SD)

FIG. 1

Parkinsonian Symptoms– UPDRS-III Scale

Variable	Difference		
	2.5 mg - Test session 1	5 mg - Test session 1	7.5 mg - Test session 1
Primary Analysis			
Change within test session in highest observed UPDRS from prior to after study	-2.66 (6.96)	0.127 (5.730)	1.49 (7.56)
	p=0.1941	p=0.5868	p=0.2576
UPDRS prior study medication	1.42 (10.13)	1.17 (10.77)	-1.78 (8.64)
	p=0.6029	p=0.7377	p=0.3633
Highest observed UPDRS after study medication	-1.24 (7.03)	1.29 (8.80)	-0.290 (7.822)
	p=0.2278	p=0.7926	p=0.9172
Secondary Analysis			
Mean AUC $_{(0\text{-}3h)}$ of UPDRS	-0.223 (3.802)	-0.218 (4.469)	-0.171 (4.006)
	p=0.4616	p=0.5226	p=0.9661

FIG. 2